Skip to content. | Skip to navigation

Personal tools


Dr. Rebecca A. Gladdy

Mount Sinai Hospital
Joseph & Wolf Lebovic Health Complex
600 University Avenue
Toronto, Ontario
M5G 1X5

Tel.: 416-586-4800

► Send Email

► Lab Website

► Web of Science Researcher ID


► Publons ID

► Publications


Dr. Rebecca A. Gladdy


Soft tissue sarcomas (STS) are a diverse group of tumors derived from connective tissue (muscle, fat and bone).

Current treatment of STS is limited primarily to surgical procedures (e.g., removing the sarcoma), with selective use of radiation therapy and the use of conventional chemotherapy in some subtypes of the disease. Unfortunately, these treatment options are limited in their effectiveness and more than 50 per cent of STS patients succumb to this disease.

Researchers have recognized that there is an urgent need to develop subtype-specific molecularly targeted therapeutics that can provide new treatment options unique to each histologic type of sarcoma.

Our program has focused on developing novel therapies for: rhabdomyosarcoma, a tumor mainly found in children and adult sarcomas including leiomyosarcoma and undifferentiated pleomorphic sarcoma.

At a Glance

Appointed to the Department of Surgery at Mount Sinai Hospital

Surgical oncologist specializing in sarcoma

Director of the GI Sarcoma Clinical Research Program

Co-Chair of the Toronto International Sarcoma Symposium 

Major Research Activities

The main goals of our Translational Sarcoma Research Program are:

to identify targeted agents through the use of high-throughput screens of sarcoma cell lines in the SMART facility at the Lunenfeld-Tanenbaum Research Institute with further validation in the Gladdy lab

to develop faithful and genetically flexible mouse models of sarcoma as a tool to functionally validate genomic data and for pre-clinical drug testing

to readily translate laboratory findings via clinical trials to sarcoma patients in Ontario.